Hereditary leiomyomatosis renal cell carcinoma: A rare case report

We present a case of a young male who experienced multiple metastases and been diagnosed HLRCC after the operation of radical nephrectomy for 10 months. This case remains us that early screening and surveillance are recommended to people who have a family history or at risk of HLRCC, surgical and palliative therapy still play an important role in clinical treatment in the meantime.
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research

Related Links:

Purpose of review Metastatic renal cell carcinoma (mRCC) has traditionally been treated with a combination of targeted systemic therapy and cytoreductive nephrectomy. This approach has recently become a topic of debate, because of new randomized data suggesting a lack of survival benefit for cytoreductive nephrectomy. We review the literature relevant to cytoreductive nephrectomy in the modern era of targeted and immune systemic therapy, and discuss the ongoing role of surgery for treatment of patients with mRCC. Recent findings Randomized trials in the cytokine era of systemic therapy for mRCC demonstrated a survival...
Source: Current Opinion in Supportive and Palliative Care - Category: Palliative Care Tags: RENAL AND UROLOGICAL PROBLEMS: Edited by Fred Saad Source Type: research
ConclusionThis case highlights the unique behavior of chRCC with an unusual site of metastasis, and the necessity of long-term follow-up after primary tumor removal, even if it is known for a low-grade metastatic potential and a relatively good prognosis.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
ConclusionsEven if cancer-to-cancer metastasis is a  very rare phenomenon, the simultaneous or consecutive finding of a renal tumor in women with breast cancer should be carefully evaluated.
Source: Wiener Medizinische Wochenschrift - Category: General Medicine Source Type: research
BACKGROUND: Novel targeted treatments and immunotherapies have substantially changed therapeutic options for advanced and metastatic renal cell carcinomas (RCCs). However, accurate diagnostic tests for the identification of high-risk patients are urgently needed. Here, we analyzed SHOX2 mRNA expression in RCC tissues and SHOX2 gene body methylation quantitatively in circulating cell-free DNA (ccfDNA) and RCC tissues with regard to risk stratification. METHODS: The clinical performance of SHOX2 methylation was tested retrospectively and prospectively in a training and testing cohort of RCC tissue samples (n = 760 in total)...
Source: Clinical Chemistry - Category: Chemistry Authors: Tags: Molecular Diagnostics and Genetics Cancer Diagnostics Source Type: research
Abstract Between 15 and 20 % of patients diagnosed with renal cell carcinoma suffer from metastatic disease by the time of diagnosis. In addition to systemic therapy, there are various surgical strategies to treat the primary tumour, e. g. cytoreductive nephrectomy (CN) or palliative nephrectomy (PN). In the immunotherapy era, the standard treatment was to perform CN followed by interferon therapy, based on 2 prospective randomised trials and their combined analysis. Since the introduction of targeted therapy around 2005, data of that quality has been missing and clinicians have had to rely on big retrospectiv...
Source: Aktuelle Urologie - Category: Urology & Nephrology Authors: Tags: Aktuelle Urol Source Type: research
We report the case of a 51-year-old Thai female presented with right abdominal mass with pain and anemia. The radiographic findings showed ruptured renal mass. She underwent radical nephrectomy and the pathological report was malignant neuroendocrine tumor. Palliative chemotherapy was administered. The patient passed away three months after the operation. Renal neuroendocrine tumors are rare. Moreover, ruptured renal tumors are very rare. They are usually considered to be angiomyolipoma or renal cell carcinoma. Poor differentiation and rupture at presentation are aggressive features of tumors. To the best of our knowledge,...
Source: Journal of the Medical Association of Thailand = Chotmaihet thangphaet - Category: General Medicine Tags: J Med Assoc Thai Source Type: research
We describe the case of a 60-year-old man with a large mass at the site of abdominal incision for a nephrectomy. The operation was performed for infection in an obstructed kidney, which in retrospect harbored malignancy. Percutaneous core biopsy of the mass revealed metastatic conventional renal cell carcinoma (RCC). Surgical resection was obviated by the presence of nodal disease on imaging. Palliative targeted therapy with tyrosine kinase inhibitor was initiated. RCC can not only mimic an inflammatory renal mass radiologically but also coexist with infective renal conditions. Diligent histopathological examination as a r...
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
Authors: Ball MW Abstract Despite advances in systemic therapy for metastatic renal cell carcinoma, durable responses remain rare and surgical management remains a mainstay of treatment for many patients with metastatic disease. Management of the primary tumor in metastatic patients can occur as 1) palliative nephrectomy for symptomatic patients in whom cure is not achievable, 2) cytoreductive nephrectomy before systemic therapy, or 3) consolidative nephrectomy after systemic therapy. Palliative nephrectomy is rarely performed in centers where angioembolization is available. The evidence for cytoreductive nephrecto...
Source: Discovery Medicine - Category: Research Tags: Discov Med Source Type: research
Conclusions Patients treated with NEP associated to systemic treatment and with an intermediate/low risk in the Motzer classification had a better PFS and OS. The OS also improves in patients treated with mTOR in second line, and Karnofsky performance status >80% in the univariate study, but not in the multivariable one.
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
In the pre‐targeted therapy era, palliative cytoreductive nephrectomy combined with cytokine immunotherapy was the standard treatment protocol for the management of metastatic renal cell carcinoma. The introduction of targeted therapies has improved response rates, median survival and overall prognosis when compared to immunotherapy. The role of cytoreductive nephrectomy in providing an independent survival advantage when used alongside immunotherapy has been demonstrated by two randomised controlled trials. However, with the new shift in improved treatment outcomes from cytokine immunotherapy to targeted therapies, the ...
Source: BJU International - Category: Urology & Nephrology Authors: Tags: Review Source Type: research
More News: Cancer & Oncology | Carcinoma | Genetics | Kidney Cancer | Nephrectomy | Palliative | Renal Cell Carcinoma | Urology & Nephrology